Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 47Lung Neoplasms 43Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 26Multiple Myeloma 24Glioma 22Pancreatic Neoplasms 21Carcinoma, Renal Cell 21Lymphoma, Large B-Cell, Diffuse 20Ovarian Neoplasms 19Melanoma 19Glioblastoma 19Squamous Cell Carcinoma of Head and Neck 18Lymphoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Triple Negative Breast Neoplasms 14Brain Neoplasms 14Fallopian Tube Neoplasms 13Carcinoma 13Laryngeal Neoplasms 12Carcinoma, Hepatocellular 12Astrocytoma 12Leukemia, Myeloid, Acute 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10

Interventions

pembrolizumab 6avelumab 6Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 3Biopsy 3prednylidene 2lutetium Lu 177 dotatate 2deltacortene 2Prednisone 2Ipilimumab 2CTLA-4 Antigen 2talimogene laherparepvec 1lenvatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1aldesleukin 1Tacrolimus 1Sirolimus 1Saline Solution 1Radiotherapy 1Radiosurgery 1MAPRE1 protein, human 1Lutetium-177 1Laparoscopy 1Exercise Test 1Cyclophosphamide 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡